ReviewEye (London, England)2022
Disentangling the association between retinal non-perfusion and anti-VEGF agents in diabetic retinopathy.
Review in Eye (London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Aflibercept versus ranibizumab for diabetic macular edema: A meta-analysis.European journal of ophthalmology · 2024Pooled it
- MAGIC: Study Design and Rationale for the Phase 2 Clinical Trial of Faricimab for Non-Proliferative Diabetic Retinopathy.Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde · 2026Trial
- Circular RNA circPSEN1 promotes neovascularization by regulating the miR-150-5p/TRIM65 axis in diabetic retinopathy.Biochemistry and biophysics reports · 2026Article
- Endothelial cell-derived microRNAs-containing extracellular vesicles and diabetic retinopathy in a mouse model of diabetes.In vitro cellular & developmental biology. Animal · 2026Article
- Tracer Techniques in Ophthalmology: Ocular Applications and Systemic Connections.Diagnostics (Basel, Switzerland) · 2026Review
- Quantifying changes in retinal non-perfusion over time with ultra-widefield fluorescein angiography following intravitreal treatment of diabetic retinopathy.BMC ophthalmology · 2026Article
- Comparative analysis of activation of macrophages/microglia in diabetic retinopathy and Familial Exudative Vitreoretinopathy.Biochemistry and biophysics reports · 2026Article
- Link Between Baseline Peripheral Vascular Leakage and Treatment Response in Patients with Central Retinal Vein Occlusion: A Pilot Study.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Impact of Comorbid Hypertension and Diabetes on Anti-VEGF Treatment Outcomes in Macular Edema.Journal of ophthalmology · 2026Article
- XBP1s-Orchestrated Soluble Mediators: Participants of Oxidative Stress in Renal Ischemia-Reperfusion Injury Following Donation After Circulatory Death.Mediators of inflammation · 2026Review
- Prostaglandin EFrontiers in medicine · 2026Review
- New targets in diabetic retinopathy: addressing limitations of current treatments through the Sema3A/Nrp1 pathway.Eye (London, England) · 2025Review
- Long-Term Effects of Anti-VEGF Therapy versus Panretinal Photocoagulation on Retinal Vessel Caliber in Eyes with Proliferative Diabetic Retinopathy.Ophthalmology. Retina · 2025Article
- Pars Plana Vitrectomy Combined with Anti-VEGF Injections as an Approach to Treat Proliferative Diabetic Retinopathy.Journal of clinical medicine · 2025Article
- Modulation of Oxidative Stress in Diabetic Retinopathy: Therapeutic Role of Natural Polyphenols.Antioxidants (Basel, Switzerland) · 2025Review
- Efficacy of Faricimab in the Treatment of Diabetic Macular Edema and Faricimab-Related Changes in OCT and OCT Angiography.Pharmaceutics · 2025Article
- The HAT Inhibitor ISOX-DUAL Diminishes Ischemic Areas in a Mouse Model of Oxygen-Induced Retinopathy.Genes to cells : devoted to molecular & cellular mechanisms · 2025Article
- Causal Associations of Smoking, Alcohol, Obesity, Sedentary Behavior, Hypertension, and Hyperglycemia With Retinal Vein Occlusion: A Mendelian Randomization Study.Current genomics · 2025Article
- Article
- Single-Cell Multiomics Profiling Reveals Heterogeneity of Müller Cells in the Oxygen-Induced Retinopathy Model.Investigative ophthalmology & visual science · 2024Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic retinopathy (DR) is the most common microvascular complication of diabetes mellitus (DM) and the leading cause of blindness in patients with DM. In the pathogenesis of DR, chronic hyperglycemia leads to biochemical and structural alterations in retinal blood vessels' wall, resulting in hyperpermeability and non-perfusion. Since vascular endothelial growth factor (VEGF) has been found to play a significant role in the pathogenesis of DR, this review sheds light on the effect of intravitreal anti-VEGF agents on retinal non-perfusion in patients with DR. Based on the existing literature, anti-VEGF agents have been shown to improve DR severity, although they cannot reverse retinal ischemia. The results of the published studies are controversial and differ based on the location of retinal non-perfusion, as well as the imaging modality used to assess retinal non-perfusion. In cases of macular non-perfusion, most of studies showed no change in both fundus fluorescein angiography (FFA) and optical coherence tomography (OCTA) in patients with DR treated with intravitreal anti-VEGF agents, while few studies reported worsening of non-perfusion with enlargement of foveal avascular zone (FAZ). Regarding peripheral ischemia, studies using wide-field-FFA demonstrated an improvement or stability in non-perfusion areas after anti-VEGF treatment. However, the use of wide-field-OCTA revealed no signs of re-perfusion of retinal vessels post anti-VEGF treatment. Further prospective studies with long follow-up and large sample size are still needed to draw solid conclusions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.